The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension: A 1-Year, Double-blind, Placebo-Controlled, Multicenter Trial
Abstract
BACKGROUND: Obesity is a highly prevalent medical condition and is commonly accompanied by hypertension. This study assessed the efficacy and safety of treatment with sibutramine hydrochloride for promoting and maintaining weight loss in obese patients with controlled hypertension, including a subset analysis of African American patients. PATIENTS AND METHODS: Obese patients with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) between 27 and 40 and a history of hypertension controlled with a calcium channel blocker (with or without concomitant thiazide diuretic treatment) were randomized to receive sibutramine (n = 150) or placebo (n = 74) with minimal behavioral intervention for 52 weeks. African Americans constituted 36% of enrolled patients. Efficacy assessments were body weight and related parameters (BMI and waist and hip circumferences), metabolic parameters (serum levels of triglycerides, high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol, glucose, and uric acid), and quality-of-life measures. Safety assessments included recording of blood pressure, pulse rate, adverse events, and reasons for discontinuation. RESULTS: For patients receiving sibutramine, weight loss occurred during the first 6 months of the trial and was maintained to the end of the 12-month treatment period. Among patients receiving sibutramine, 40.1% lost 5% or more of body weight (5% responders) and 13.4% lost 10% or more of body weight (10% responders) compared with 8.7% and 4.3% of patients in the placebo group, respectively (P<.05). Changes in body weight were similar among African Americans and whites. Sibutramine-induced weight loss was associated with significant improvements in serum levels of triglycerides, HDL-C, glucose, and uric acid. Waist circumference and quality-of-life measures also improved significantly in patients receiving sibutramine. Sibutramine-treated patients had small but statistically significant mean increases in diastolic blood pressure (2.0 mm Hg) and pulse rate (4.9 beats/min) compared with placebo-treated patients (-1.3 mm Hg and 0.0 beats/min; P<.05); these changes were similar among African Americans and whites. Most adverse events were mild to moderate in severity and transient. The most common adverse event resulting in discontinuation among patients receiving sibutramine was hypertension (5.3% of patients receiving sibutramine vs 1.4% of patients receiving placebo). CONCLUSIONS: In obese patients with controlled hypertension, sibutramine was an effective and well-tolerated treatment for weight loss and maintenance. Sibutramine-induced weight loss resulted in improvements in serum levels of triglycerides, HDL-C, uric acid, and glucose, and in waist circumference and quality-of-life measures. Blood pressure and heart rate increased by a small amount. Efficacy and safety profiles for sibutramine among African American and white obese patients with controlled hypertension were similar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
Weight, Weight Change, and Coronary Heart Disease in Women: Risk Within the 'Normal' Weight Range
Willett, W. C. (1995) · JAMA · doi:10.1001/jama.1995.03520300035033 · Cited by 924
Carey, V. J., Walters, E. E., Colditz, G. A., Solomon, C. G., Willet, W. C., Rosner, B. A., Speizer, F. E., & Manson, J. E. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009158 · Cited by 827
Incidence and precursors of hypertension in young adults: The Framingham offspring study
Garrison, R. J., Kannel, W. B., Stokes, J., & Castelli, W. P. (1987) · Preventive Medicine · doi:10.1016/0091-7435(87)90087-9 · Cited by 789 · cited 2×
“Obesity increases the risk for cardiovascular disease (CVD), acting partly via hypertension, dyslipidemia, and type 2 diabetes mellitus, which occur commonly in obese subjects.(5-13) Cardiovascular disease risk is also increased by obesity independently of other risk factors.”
BackgroundA Prospective Study of Body Mass Index, Weight Change, and Risk of Stroke in Women
Rexrode, K. M. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540430051032 · Cited by 617
The Insulin Resistance—Dyslipidemic Syndrome of Visceral Obesity: Effect on Patients' Risk
Després, J. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00683.x · Cited by 261 · cited 3×
“(%) Women 92 (61) 44 (60) Men 58 (39) 30 (40) Race, No.”
Background
Cited by
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Kolotkin, R. L., Meter, K., & Williams, G. R. (2001) · Obesity Reviews · doi:10.1046/j.1467-789x.2001.00040.x · Cited by 700
Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665
McTigue, K. M., Harris, R., Hemphill, B., Lux, L., Sutton, S., Bunton, A. J., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00013 · Cited by 603
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Diabetes and Hypertension in Severe Obesity and Effects of Gastric Bypass-Induced Weight Loss
Sugerman, H. J., Wolfe, L. G., Sica, D. A., & Clore, J. N. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000071560.76194.11 · Cited by 503
Serotonin and Blood Pressure Regulation
Watts, S. W., Morrison, S. F., Davis, R. P., & Barman, S. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004697 · Cited by 396
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Padwal, R., Li, S. K., & Lau, D. C. W. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802475 · Cited by 348
Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease
Parekh, S., & Anania, F. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.055 · Cited by 340
The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco, C., Parrott, M. A., & Raskin, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.134 · Cited by 326
Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment??of Obesity
Halford, J. C. G., Harrold, J. A., Boyland, E. J., Lawton, C. L., & Blundell, J. E. (2007) · Drugs · doi:10.2165/00003495-200767010-00004 · Cited by 307
Weight Loss of Black, White, and Hispanic Men and Women in the Diabetes Prevention Program
West, D. S., Prewitt, T. E., Bursac, Z., & Felix, H. C. (2008) · Obesity · doi:10.1038/oby.2008.224 · Cited by 295
Anesthetic Considerations for Bariatric Surgery
Ogunnaike, B. O., Jones, S. B., Jones, D. B., Provost, D., & Whitten, C. W. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200212000-00061 · Cited by 293
AGA technical review on obesity
Klein, S., Wadden, T., & Sugerman, H. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35514 · Cited by 274
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Pharmacological Therapies for Obesity
Kaplan, L. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.002 · Cited by 149
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea
Yee, B. J., Phillips, C. L., Banerjee, D., Caterson, I., Hedner, J. A., & Grunstein, R. R. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803363 · Cited by 87
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“In this trial, bodyweight loss stabilized by approximately 36 weeks,(25) which was similar to that seen in trials of orlistat or the noradrenergic drug sibutramine.(26,27) Previous pharmacological agents approved for the treatment of obesity, including amphetamine”
ResultLong-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Effects of the sibutramine therapy on pulmonary artery pressure in obese patients
Guven, A., Koksal, N., Cetinkaya, A., Sokmen, G., & Ozdemir, R. (2004) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00314.x · Cited by 20
Fabbrini, E., & Klein, S. (2008) · Clinical Cornerstone · doi:10.1016/s1098-3597(08)60027-7 · Cited by 9
Obesity, weight reduction and survival in heart failure: reply
Fonarow, G. C., Horwich, T. B., Hamilton, M. A., MacLellan, W. R., & Tillisch, J. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01807-7 · Cited by 7
Metadata
- Authors
- McMahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F., & Mooradian, A. D.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-07-24
- Volume
- 160
- Issue
- 14
- Pages
- 2185
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2101243738
- Cited by
- 247
- References
- 7
- FWCI
- 15.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.